CompletedNCT00988949
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
Medication studyAges 21–55SingaporeBipolarity
Understand this study
Who was this study for?
Listed age limits: 21 years to 55 years.
- Listed locations
- SingaporeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNovember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Singapore
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT00988949
- Official title
Show the full official title
Phase I, Randomized, Placebo Controlled Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release In Healthy Male Adult Subjects
Recruitment & locations
CompletedSingapore
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including PF-04455242 and spiradoline.
Who was this study for?
Listed age limits: 21 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me